Sugi Predict

Sugi Predict / Compounds / SCHEMBL8192425

SCHEMBL8192425

SCHEMBL8192425

CN(C)CC[C@H](N)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOS2 P35228 2/20 0.53
▸ NOS3 P29474 1/20 0.53
▸ NOS1 P29475 1/20 0.53
▸ GSR P00390 2/20 0.50
▸ GRM8 O00222 1/20 0.50
▸ GRM6 O15303 1/20 0.50
▸ GRIN2D O15399 1/20 0.50
▸ GRIN3B O60391 1/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ GRIK1 P39086 1/20 0.50
▸ GRM5 P41594 1/20 0.50
▸ GRIA1 P42261 1/20 0.50
▸ GRIA2 P42262 1/20 0.50
▸ GRIA3 P42263 1/20 0.50
▸ SLC1A3 P43003 1/20 0.50
▸ SLC1A2 P43004 1/20 0.50
▸ SLC1A1 P43005 1/20 0.50
▸ GRIA4 P48058 1/20 0.50
▸ GRIN1 Q05586 1/20 0.50
▸ GRIN2A Q12879 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1527366 1.00 NOS2 (0.53) NOS2NOS3NOS1GSRGRM8
SCHEMBL1527367 1.00 NOS2 (0.53) NOS2NOS3NOS1GSRGRM8
Hydrochloric Acid SCHEMBL11227491 0.98 NOS2 (0.52) NOS2NOS3NOS1GSRGRM8
SCHEMBL1527395 0.86 NOS2 (0.65) NOS2NOS3NOS1GSRGRM8
SCHEMBL1527394 0.86 NOS2 (0.65) NOS2NOS3NOS1GSRGRM8
SCHEMBL25629375 0.86 NOS2 (0.65) NOS2NOS3NOS1GSRGRM8
SCHEMBL358975 0.85 NOS2 (0.58) NOS2NOS3NOS1GSRCYP1A2
SCHEMBL881063 0.85 NOS2 (0.58) NOS2NOS3NOS1GSRCYP1A2
SCHEMBL1527409 0.85 NOS2 (0.58) NOS2NOS3NOS1GSRCYP1A2
Hydrochloric Acid SCHEMBL8127399 0.85 NOS2 (0.62) NOS2NOS3NOS1GSRCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4745237-A1 RNAI AGENT FOR INHIBITING EXPRESSION OF KETOHEXOKINASE AND USE THEREOF YUN HO BIO CO., LTD (CN) 2026-05-20 — — EP claimed
WO-2025082461-A1 POLYPEPTIDE, BIOACTIVE CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF 优洛生物(上海)有限公司 2025-04-24 — — WO claimed
WO-2025016294-A1 RNAI AGENT FOR INHIBITING EXPRESSION OF KETOHEXOKINASE AND USE THEREOF 云合智药（苏州）生物科技有限公司 2025-01-23 — — WO claimed
CN-118804921-A Conjugate, ligand unit and use thereof 云合智药（苏州）生物科技有限公司 2024-10-18 — — CN claimed
WO-2024152775-A1 CONJUGATE, LIGAND UNIT AND USE THEREOF 云合智药（苏州）生物科技有限公司 2024-07-25 — — WO claimed
US-20230257343-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2023-08-17 — — US claimed
EP-4745237-A1 RNAI AGENT FOR INHIBITING EXPRESSION OF KETOHEXOKINASE AND USE THEREOF YUN HO BIO CO., LTD (CN) 2026-05-20 — — EP disclosed
WO-2025082461-A1 POLYPEPTIDE, BIOACTIVE CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF 优洛生物(上海)有限公司 2025-04-24 — — WO disclosed
WO-2025016294-A1 RNAI AGENT FOR INHIBITING EXPRESSION OF KETOHEXOKINASE AND USE THEREOF 云合智药（苏州）生物科技有限公司 2025-01-23 — — WO disclosed
CN-118804921-A Conjugate, ligand unit and use thereof 云合智药（苏州）生物科技有限公司 2024-10-18 — — CN disclosed
WO-2024152775-A1 CONJUGATE, LIGAND UNIT AND USE THEREOF 云合智药（苏州）生物科技有限公司 2024-07-25 — — WO disclosed
US-20240199692-A1 POLYPEPTIDE HAVING MMP2-INHIBITORY EFFECT TAISHO PHARMACEUTICAL CO., LTD. (JP) 2024-06-20 — — US disclosed
US-20230257343-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2023-08-17 — — US disclosed
US-20100016238-A1 Peptides for Use in the Treatment of Obesity NOVO NORDISK A/S (DK) 2010-01-21 — — US disclosed
US-20100016238-A1 Peptides for Use in the Treatment of Obesity NOVO NORDISK A/S (DK) 2010-01-21 — — US disclosed
US-20100016237-A1 Novel Peptides for Use in the Treatment of Obesity NOVO NORDISK A/S (DK) 2010-01-21 — — US disclosed
WO-2008087186-A2 PEPTIDES FOR USE IN THE TREATMENT OF OBESITY NOVO NORDISK A/S (DK) 2008-07-24 — — WO disclosed
WO-2008087187-A1 PEPTIDES FOR USE IN THE TREATMENT OF OBESITY NOVO NORDISK A/S (DK) 2008-07-24 — — WO disclosed
WO-2008021927-A2 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2008-02-21 — — WO disclosed
CN-1538951-A Omega-aminoalkylamides of R-2-aryl-propionic acids as inhibitors of chemotaxis of polymorphonucleate and mononucleate cells ��ķ�ɷ����޹�˾ 2004-10-20 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199692-A1 POLYPEPTIDE HAVING MMP2-INHIBITORY EFFECT MMP2, MMP26, MMP25 NOS2 714/4885NOS3 958/4885NOS1 1569/4885
US-20100016238-A1 Peptides for Use in the Treatment of Obesity MC4R, GIPR, MC3R NOS2 2187/4885NOS3 1297/4885NOS1 2215/4885
US-20100016237-A1 Novel Peptides for Use in the Treatment of Obesity MC4R, MC3R, GIPR NOS2 2658/4885NOS3 1873/4885NOS1 2664/4885
US-20230257343-A1 NOVEL AMINO ACID DERIVATIVES DNPEP, BCAT1, ANPEP NOS2 880/4885NOS3 1214/4885NOS1 1488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.